EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years

Concha Amador, Juan Ambrosioni, Luz Martín-Carbonero, Carmen Hidalgo-Tenorio, Juan Tiraboschi, Santiago Moreno

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026

DOI: 10.1016/j.eimce.2026.503056 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026. Verfasst von Concha Amador und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Hospital Marina Baixa, Villajoyosa, Alicante, Spain. Hauptthemen laut MEDLINE: HIV Infections, Emtricitabine, Anti-HIV Agents, Tenofovir. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrase strand inhibitor (INSTI)-based antiretroviral regimens are the preferred choices for treating people with human immunodeficiency virus (PWH). The once-daily single-tablet combination of INSTI bictegravir, co-formulated with emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), has shown effectiveness and good tolerability in randomized clinical trials, both in treatment-naïve (TN) and virologically suppressed patients switched to this regimen. Real-world evidence represents clinical practice and may fill data gaps left by pivotal studies. Based on literature search for real-world studies in Spain within five years, and using clinical trial data as a contextual framework, this narrative review synthesizes observational experience with BIC/FTC/TAF, focusing on the interplay between comorbidities, advanced age, and treatment outcomes from underrepresented subgroups in clinical trials. This fixed-dose combination proved effective and well-tolerated for TN and treatment-experienced PWH, with low virological failure even in difficult-to-treat patients. Low rates of treatment discontinuations due to adverse events or drug-drug interactions aligned with clinical trial findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsEmtricitabineAnti-HIV AgentsTenofovirAdenineHeterocyclic Compounds, 4 or More RingsHumansSpainDrug CombinationsAmidesPiperazinesPyridonesAlanineHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

Antiretroviral therapyBictegravirCombinación de dosis fijasEfectividadEffectivenessEvidencia del mundo realFixed-dose combinationReal-wordl evidenceSafetySeguridadTerapia antirretroviral

Substanzen

EmtricitabineDrug CombinationsAnti-HIV AgentsTenofovirAdenineAmidesPiperazinesPyridonesbictegravirAlanine

Autor:innen und Institutionen

  • Infectious Diseases Unit, Hospital Marina Baixa, Villajoyosa, Alicante, Spain.
  • HIV Unit, Infectious Diseases Service, Hospital Clinic-Fundació de recerca Clinic Barcelona - Institut de investigacions BiomediquesAugust Pi i Sunyer, Barcelona, Spain; CIBER INFEC, Instituto de Salud Carlos III, Madri…
  • CIBER INFEC, Instituto de Salud Carlos III, Madrid, Spain; HIV Unit, Internal Medicine, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Electronic address: lmcarbonero@gmail.com.
  • Infectious Diseases Department, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitario de Granada (IBS-Granada), Granada, Spain.
  • HIV Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
  • CIBER INFEC, Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain; Department of Medicine, Alcalá University, Madrid, Spain.

Zitieren

APA

Amador, C., Ambrosioni, J., Martín-Carbonero, L., Hidalgo-Tenorio, C., Tiraboschi, J., & Moreno, S. (2026). Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2026.503056

Vancouver

Amador C, Ambrosioni J, Martín-Carbonero L, Hidalgo-Tenorio C, Tiraboschi J, Moreno S. Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026. doi:10.1016/j.eimce.2026.503056

BibTeX
@article{Amador2026,
  author = {Amador, Concha and Ambrosioni, Juan and Martín-Carbonero, Luz and Hidalgo-Tenorio, Carmen and Tiraboschi, Juan and Moreno, Santiago},
  title = {Bictegravir/emtricitabine/tenofovir alafenamide: A review of the real-world experience in Spain within the last five years},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2026},
  doi = {10.1016/j.eimce.2026.503056}
}
Kostenlos starten →